SEC Form 4 · accession 0001022079-18-000096

QUEST DIAGNOSTICS INC · DGX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Jon R Cohen

Officer — SVP & Group Exec. Diag. Sol.

Period of report

Mar 8, 2018

Accepted (ET)

Mar 12, 2018 · 4:33 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001022079

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 8, 2018	M	38,928	$66.51	A	115,426	D
Common Stock^F2	Mar 8, 2018	S	18,037	$104.085	D	97,389	D
Common Stock^F3	Mar 8, 2018	S	1,427	$104.76	D	95,962	D
Common Stock^F4	Mar 8, 2018	S	18,164	$104.088	D	77,798	D
Common Stock^F5	Mar 8, 2018	S	1,300	$104.767	D	76,498	D
Common Stock^F6	Mar 8, 2018	S	34,168	$104.088	D	42,330	D
Common Stock^F7	Mar 8, 2018	S	2,800	$104.77	D	39,530	D
Common Stock	Mar 8, 2018	S	7,773	$104.77	D	31,757	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualifed Stock Option (right to buy)^F8	$66.51	Mar 8, 2018	M	38,928	D	—	Feb 25, 2026	Common Stock	38,928	19,464	D

Explanation of responses

F1This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2018.
F2This transaction was executed in multiple trades at prices ranging from $103.65 to $104.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $104.66 to $104.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4This transaction was executed in multiple trades at prices ranging from $103.68 to $104.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5This transaction was executed in multiple trades at prices ranging from $104.70 to $104.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6This transaction was executed in multiple trades at prices ranging from $103.65 to $104.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7This transaction was executed in multiple trades at prices ranging from $104.70 to $104.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.